Marconi, G., Piciocchi, A., Audisio, E., Priolo, G., Papayannidis, C., Martelli, M., . . . Martinelli, G. (2022). Gimema AML1718 Part 1: Planned Interim Analysis of a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia. Blood, 140(Supplement 1), 1705-1707. https://doi.org/10.1182/blood-2022-157393

Marconi, Giovanni, et al. "Gimema AML1718 Part 1: Planned Interim Analysis of a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia." Blood 140, no. Supplement 1 (2022): 1705-1707. https://doi.org/10.1182/blood-2022-157393.

Marconi, Giovanni, et al. "Gimema AML1718 Part 1: Planned Interim Analysis of a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia." Blood, vol. 140, no. Supplement 1, 2022, pp. 1705-1707, https://doi.org/10.1182/blood-2022-157393.